Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that the first person with multiple sclerosis (MS) has been scanned in a joint study with Massachusetts General Hospital (MGH) scientists to validate a novel positron emission tomography (PET) imaging technique to monitor myelin integrity and demyelination in MS. The study is evaluating the PET tracer [¹⁸F]3F4AP, which was developed by Dr. Pedro Brugarolas, an investigator in the department of Radiology at MGH and Assistant Professor at Harvard Medical School. In previous studies in animals and humans, [¹⁸F]3F4AP was found to be highly sensitive to demyelinated lesions and have favourable pharmacokinetics, suggesting that it holds promise as a biomarker to monitor changes in demyelination in response to remyelinating or neuroprotective drugs in MS.

Read more at globenewswire.com